Guardion Health Sciences, Inc. (NASDAQ:GHSI – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 67,800 shares, a decline of 14.7% from the June 30th total of 79,500 shares. Based on an average daily volume of 5,700 shares, the short-interest ratio is currently 11.9 days. Currently, 6.7% of the shares of the stock are short sold.
Guardion Health Sciences Price Performance
GHSI traded up $0.06 on Monday, reaching $9.63. 1,747 shares of the company’s stock were exchanged, compared to its average volume of 98,782. The stock has a market cap of $12.36 million, a PE ratio of -2.40 and a beta of 0.91. Guardion Health Sciences has a twelve month low of $5.01 and a twelve month high of $10.75. The stock’s fifty day moving average price is $9.75 and its 200-day moving average price is $8.53.
Guardion Health Sciences (NASDAQ:GHSI – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($3.71) earnings per share for the quarter. The business had revenue of $3.00 million for the quarter. Guardion Health Sciences had a negative return on equity of 77.29% and a negative net margin of 16.69%.
About Guardion Health Sciences
Guardion Health Sciences, Inc, a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment.
Read More
- Five stocks we like better than Guardion Health Sciences
- Investing in Travel Stocks Benefits
- Survey: Top 175 Fittest Retirement Locations in America
- EV Stocks and How to Profit from Them
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What to Know About Investing in Penny Stocks
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.